)
)
)
.png)
Duo Oncology is an oncology company reimagining chemotherapy, a foundational treatment for metastatic cancer. Its lead program, DUO-207, consolidates multi-drug chemotherapy regimens into a single, potent prodrug for pancreatic, lung, breast, and other inoperable cancers. DUO-207 is trial-ready, supported by completed IND-enabling studies, orphan designations, and strong preclinical benchmarks versus standard of care. Duo has secured strategic investment from BeOne Medicines, received multiple SBIR awards, and was selected for the NCI NanoCharacterization Program and the NIH Investor Initiative. Following a favorable FDA pre-IND meeting, Duo is preparing an efficient first-in-human program that begins at Phase 1b and expands into Phase 2 after enrolling the initial nine patients. This capital-efficient strategy is focused on generating early clinical data to support strategic partnering or acquisition within the next three years.
Year Founded
2020
Next catalyst (value inflection) update
Phase 1b dose escalation safety and tolerability data in minimally treated patients.
Expected time of next catalyst update
Dec-26
City
Pittsburgh
Country
United States
Company CEO or top company official
Sam Rothstein
Development Phase of Primary Product
Pre-Clinical
Lead Product in Development
DUO-207 polymer conjugate prodrug of paclitaxel and gemcitabine. A single iv infusion for pancreatic, lung and breast cancer.
Number of Unlicensed Products
DUO-207 DUO-307 DUO-209
Therapeutic Area
Oncology
Website
http://www.DuoOncology.com
){kind=logo}
)
)
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}
){kind=logo}
